Based on a thorough review of the scientific evidence, the U.S. Food and Drug Administration (FDA) today finalized its determination that partially hydrogenated oils (PHOs), the primary dietary source of artificial trans fat in processed foods, are not “generally recognized as safe” (GRAS) for use in food. Read more
Dexcom has partnered with recording artist and actor, Nick Jonas, who has Type 1 diabetes, to raise awareness of the benefits of continuous glucose monitoring (CGM) for people with diabetes. Jonas will share his personal story and views on living with diabetes and his use of Dexcom technology to help him monitor his glucose levels and manage his diabetes. Read more
The Type 1 Diabetes Program of The Leona M. and Harry B. Helmsley Charitable Trust has announced the launch of the Diabetes Data Innovation Initiative through which it will provide up to $5 million in funding over the next two years. The funding will go to innovative solutions that enable the use of data to ease the burden of type 1 diabetes (T1D) for those living with the disease, their caregivers and healthcare providers. Read more
Asante Solutions announced that it is ceasing all business operations and will no longer sell or support the Asante Snap Insulin Pump. This means all current Asante Snap Insulin Pump users will soon need to transition to a new insulin pump. Read more
The U.S. Food and Drug Administration (FDA) approved Becton Dickinson Medical’s (BD) application to begin production of its novel FlowSmart insulin infusion set, designed to improve insulin delivery with less pain. The FlowSmart insulin infusion set was developed in collaboration with JDRF and the Helmsley Charitable Trust. Read more
The European Commission has granted Sanofi marketing authorization in Europe for Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), for the treatment of type 1 and type 2 diabetes mellitus in adults. Toujeo is a next-generation, once-daily basal insulin based on a broadly-used molecule (insulin glargine) with a well-established benefit-risk profile. Read more
The U.S. Food and Drug Administration (FDA) approved Sanofi’s new once daily long acting insulin, Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL) for treatment of adults living with type 1 and type 2 diabetes.
Toujeo will be available in the Toujeo SoloSTAR, a disposable prefilled pen which contains 450 units of Toujeo and requires one third of the injection volume to deliver the same number of insulin units as compared to the Lantus SoloSTAR. Read more
Janssen Research & Development, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that it will invest in a novel scientific approach, called disease interception, to find ways to intercept type 1 diabetes using new diagnostic and pre-disease intervention strategies. If successful, this approach has the potential to transform the standard of care in type 1 diabetes.
Knowing more about the type of T cell that causes type 1 is definitely good news for future treatments… Read more
The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company’s Glyxambi for treatment of adults with type 2 diabetes.
Glyxambi is the first and only diabetes treatment in the U.S. to combine the dual mechanisms of …. Read more